QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market
Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article highlighting the potential of its GelrinC cell-free hydrogel implant to address longstanding challenges in focal knee injuries through an off-the-shelf treatment designed to simplify surgical workflows, support faster recovery and promote durable tissue regeneration. The company recently received European regulatory approval for a next-generation, solvent-free manufacturing process that increases production yield by approximately 400%, supporting greater scalability and lower production costs. Regentis is also advancing surgeon training and European commercialization while progressing its pivotal U.S. Phase III SAGE trial, which is more than 50% enrolled. GelrinC’s combination of procedural simplicity, clinical…